VIDEO: Healthcare Reform Efforts and the BPCIA
by Ha Kung Wong
November 28, 2017
Ha Kung Wong, Molly Burich, Amanda Forys, and Angus Worthing discuss the potential fate of the Biologics Price Competition and Innovation Act (BPCIA) in health care reform efforts, and remark on negative feedback related to the Affordable Care Act (ACA) provision for an Independent Payment Advisory Board (IPAB) as part of The Center for Biosimilars™ Peer Exchange®.
Ha Kung Wong
has extensive experience litigating a wide variety of pharmaceutical cases, including those concerning biologics used to treat rheumatoid arthritis and autoimmune disorders. He also has extensive experience consulting, conducting due diligence and licensing pharmaceutical portfolios. Ha Kung has a B.S. in Biochemistry and a B.S. in Chemistry.